Trujillo Madison, Kharbanda Anupreet, Corley Christa, Simmons Pilar, Allen Antiño R
Division of Radiation Health, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Antioxidants (Basel). 2021 Aug 29;10(9):1383. doi: 10.3390/antiox10091383.
In the past few years, breast cancer has become the most prevalent type of cancer. The majority of patients receive combinatorial chemotherapy treatments, which may result in increased risk of developing drug resistance, a reduced quality of life, and substantial side effects. Treatment modalities that could lessen the physical toll of standard treatments or act in synergy with chemotherapeutic treatments would benefit women worldwide. Research into tocotrienols has thus far demonstrated their potential to be such an agent, with tocotrienols surpassing the pharmacological potential of tocopherols. Further research using in vitro and preclinical breast cancer models to support clinical trials is needed. This review uses bibliometric analysis to highlight this gap in research and summarizes the current and future landscape of tocotrienols as an anti-breast cancer agent.
在过去几年中，乳腺癌已成为最常见的癌症类型。大多数患者接受联合化疗治疗，这可能会增加产生耐药性的风险、降低生活质量并带来严重的副作用。能够减轻标准治疗对身体造成的负担或与化疗治疗协同作用的治疗方式将使全球女性受益。迄今为止，对生育三烯酚的研究表明它们有可能成为这样一种药物，生育三烯酚的药理潜力超过了生育酚。需要进一步使用体外和临床前乳腺癌模型进行研究以支持临床试验。本综述通过文献计量分析突出了这一研究差距，并总结了生育三烯酚作为抗乳腺癌药物的现状和未来前景。
